secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001628280-22-028759
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen Q3 net loss $0.10/share, cash $101.6M; advances OCU400 gene therapy and adds OCU500 mucosal vaccine
--------------------------------------------------------------------------------

- Net loss per share $0.10 vs $0.05 YoY; R&D $15.6M (up from $6.3M).
- Cash and equivalents $101.6M at Sep 30, 2022; provides runway into Q4 2023.
- COVAXIN Phase 2/3 enrollment completed; top-line data expected early 2023.
- OCU400 gene therapy: dosing began in Cohort 3 for retinitis pigmentosa; enrollment to complete by year-end; also to enroll LCA CEP290 patients.
- Expanded pipeline: OCU500 mucosal COVID-19 vaccine licensed from Washington University; OCU410ST for Stargardt disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000162828022028759/0001628280-22-028759-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000162828022028759/ocgn-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-028759

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer